Zydus Lifesciences Ltd

Zydus Lifesci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Zydus Lifesciences Ltd

₹ 1,088 -0.13%
08 Jun - close price
zyduscadila.com BSE: 532321 NSE: ZYDUSLIFE
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

Business Segments

Website BSE NSE
  • Market Cap ₹ 1,09,438 Cr.
  • Current Price ₹ 1,088
  • High / Low ₹ 1,116 / 836
  • Stock P/E 20.2
  • Book Value ₹ 269
  • Dividend Yield 0.09 %
  • ROCE 21.2 %
  • ROE 21.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty Next 50

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
5,011 5,140 4,369 4,505 5,534 6,208 5,237 5,269 6,528 6,574 6,123 6,864 7,587
3,755 3,634 3,223 3,403 3,903 4,124 3,776 3,882 4,402 4,485 4,107 5,048 5,033
Operating Profit 1,256 1,505 1,146 1,102 1,630 2,084 1,461 1,388 2,126 2,088 2,016 1,816 2,554
OPM % 25% 29% 26% 24% 29% 34% 28% 26% 33% 32% 33% 26% 34%
-566 21 53 60 160 63 68 57 -139 155 75 26 -263
Interest 28 18 9 20 35 32 25 32 77 85 101 130 123
Depreciation 179 180 184 195 205 215 234 229 238 238 302 360 508
Profit before tax 484 1,328 1,006 947 1,550 1,900 1,271 1,184 1,672 1,921 1,687 1,353 1,660
Tax % 28% 16% 22% 23% 21% 23% 29% 15% 25% 23% 27% 29% 19%
358 1,134 803 790 1,246 1,482 920 1,026 1,244 1,521 1,239 1,023 1,341
EPS in Rs 2.93 10.74 7.91 7.80 11.75 14.11 9.06 10.17 11.64 14.58 12.51 10.36 12.65
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
8,651 9,427 9,376 11,905 13,166 14,253 15,102 15,265 17,237 19,547 23,242 27,148
6,896 7,095 7,474 9,074 10,174 11,455 11,758 11,923 13,378 14,163 16,183 18,673
Operating Profit 1,756 2,332 1,902 2,831 2,991 2,798 3,344 3,342 3,860 5,384 7,058 8,475
OPM % 20% 25% 20% 24% 23% 20% 22% 22% 22% 28% 30% 31%
45 112 127 111 183 -264 -171 2,581 -422 293 50 -7
Interest 68 53 45 91 194 342 164 127 130 81 166 439
Depreciation 287 292 373 539 599 696 725 713 723 764 916 1,408
Profit before tax 1,446 2,099 1,612 2,312 2,382 1,495 2,285 5,084 2,585 4,832 6,027 6,621
Tax % 18% 8% 8% 24% 22% 21% 6% 10% 23% 20% 23% 24%
1,188 1,964 1,517 1,810 1,899 1,204 2,185 4,618 2,092 3,973 4,673 5,124
EPS in Rs 11.24 18.89 14.53 17.35 18.06 11.49 20.84 43.83 19.37 38.36 44.97 50.09
Dividend Payout % 21% 17% 22% 20% 19% 30% 17% 6% 31% 8% 24% 2%
Compounded Sales Growth
10 Years: 11%
5 Years: 12%
3 Years: 16%
TTM: 17%
Compounded Profit Growth
10 Years: 11%
5 Years: 19%
3 Years: 32%
TTM: 17%
Stock Price CAGR
10 Years: 13%
5 Years: 11%
3 Years: 29%
1 Year: 12%
Return on Equity
10 Years: 20%
5 Years: 21%
3 Years: 21%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 102 102 102 102 102 102 102 102 101 101 101 101
Reserves 4,149 5,597 6,858 8,642 10,284 10,273 12,890 16,897 17,415 19,729 23,852 27,011
2,651 2,442 5,207 5,407 7,899 7,986 4,584 4,221 1,195 804 3,213 12,496
2,144 2,208 2,937 3,632 4,945 5,115 6,189 6,421 6,851 8,201 9,523 12,799
Total Liabilities 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834 36,689 52,407
3,352 3,748 5,755 6,483 12,164 12,230 12,133 12,253 11,521 12,368 13,134 26,639
CWIP 798 951 1,543 1,527 837 742 783 661 1,201 2,423 2,692 1,166
Investments 154 416 435 746 674 765 830 3,288 1,547 1,220 6,408 7,540
4,743 5,235 7,371 9,028 9,556 9,740 10,019 11,439 11,294 12,822 14,456 17,062
Total Assets 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834 36,689 52,407

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
994 1,894 1,312 919 1,282 2,505 3,293 2,104 2,689 3,228 6,777 2,117
-465 -860 -2,872 -974 -3,977 -1,012 -835 1,137 1,178 -1,492 -8,377 -8,296
-351 -935 2,316 52 1,885 -1,094 -2,549 -868 -4,400 -1,810 2,014 5,807
Net Cash Flow 178 99 756 -3 -811 399 -90 2,373 -534 -75 414 -373
Free Cash Flow 498 936 -1,623 -116 236 1,617 2,446 1,050 1,697 2,345 5,116 -530
CFO/OP 79% 109% 81% 54% 65% 100% 109% 83% 85% 84% 122% 44%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 67 68 89 98 110 94 76 80 94 97 63 73
Inventory Days 175 158 193 211 208 207 227 245 197 202 227 282
Days Payable 125 154 165 167 149 151 155 141 123 125 133 142
Cash Conversion Cycle 118 71 116 142 169 150 148 184 168 175 158 212
Working Capital Days 6 -1 -34 17 10 -19 -6 19 70 88 3 37
ROCE % 23% 28% 16% 18% 15% 11% 14% 13% 15% 22% 24% 21%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Manufacturing Facilities
Number

Log in to view insights

Please log in to see hidden values.

Login
US ANDA Approvals during the year (Final & Tentative)
Number
US ANDAs Filed during the year
Number
R&D Spend as % of Revenue
%
India Field Force Strength
Number
Chronic Mix in India Formulations Business
%
US Market Prescriptions Rank (IQVIA)
Rank
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 75.00% 75.00% 75.00% 75.00% 75.00%
4.04% 4.85% 4.99% 5.72% 5.59% 7.52% 7.53% 7.31% 7.13% 7.34% 7.06% 6.95%
13.44% 13.01% 12.96% 12.55% 12.56% 10.59% 10.61% 10.95% 11.09% 10.86% 11.08% 11.20%
0.07% 0.07% 0.07% 0.07% 0.07% 0.05% 0.05% 0.05% 0.04% 0.00% 0.00% 0.00%
7.47% 7.07% 6.99% 6.66% 6.81% 6.85% 6.85% 6.69% 6.74% 6.81% 6.86% 6.86%
No. of Shareholders 3,11,7642,97,9533,06,4952,94,3243,36,3093,70,8633,65,3563,71,6193,86,1273,96,1054,03,2664,18,314

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls